Carboplatin dosage: prospective evaluation of a simple formula based on renal function. - Wikidata - awgldk - TriplyDB

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

http://www.wikidata.org/entity/Q33429552

about

Translating pharmacogenomics: challenges on the road to the clinic The average body surface area of adult cancer patients in the UK: a multicentre retrospective study Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer Nedaplatin: a cisplatin derivative in cancer chemotherapy Treatment of Elderly Patients with Squamous Cell Carcinoma of the Head and Neck Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation Estimation of glomerular filtration rate in cancer patients Population pharmacokinetics and pharmacodynamics of oral etoposide A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors Toxicology of chemically modified graphene-based materials for medical application.A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma.Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma.Toxicities of the platinum antineoplastic agents.Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.AUC of Calvert's formula in targeted intra-arterial carboplatin chemoradiotherapy for cancer of the oral cavity.Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial.Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study.A phase I and pharmacokinetic study of indisulam in combination with carboplatin A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose.A population-based clinical trial of irinotecan and Carboplatin.A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors.

P2860

Q21092371-63B11DF1-4CC7-4AF5-9F92-9EBCD4AD5313 Q21142666-7C4E066A-A230-4537-9FBF-219D84523BE4 Q24187061-916BB1B2-60C9-4FA9-BCB4-0A664DA6A62A Q24201216-8F3CF327-18D8-47A8-9552-D6B44EC082F3 Q24623561-C326CBCE-C8A2-4D89-9CA8-C9FB02A555D7 Q28076894-E609C657-2890-4069-87DE-90DADE57DE67 Q28265589-600710FA-A4C9-43E9-8853-5E1C90C1B3A5 Q28346751-A648E75D-A813-476C-86F6-9C072FE7E8DC Q28346786-E88CDDCD-CD03-417A-8FFB-AF5059AEA5BD Q28350826-5663C21A-DA24-4A2F-B362-FF970F58115C Q28365888-330D0B90-DC42-4906-A093-F762CAA8E02A Q28367780-600BD90E-C85E-47ED-B79B-F759C2E24AB5 Q28538327-38C35496-4C39-4B56-A41C-116A40BED2B2 Q28710150-19CD7447-D8CD-41C2-B9C3-66EAE010413B Q29035867-BD704534-1F58-4AA4-B512-3D36679239C8 Q30427860-966D377A-4818-4194-B260-A3A087533081 Q30430866-AB07CA95-0083-428D-B33B-566CD1A673B7 Q33287243-3D0E17BC-F708-4B9E-B3E1-076A1B367F02 Q33315395-EA953F4A-E754-4B70-B17E-6F974DE1E69C Q33328423-2785EE8A-F34A-452A-B359-9BFAF87D9601 Q33337500-F1025974-AEF6-43F5-9E86-3D5AB997FE20 Q33338538-305F30FF-B6E9-4379-B99F-D69FB359C364 Q33340192-0E4BB989-6165-4505-BCB9-C329C03C5DFE Q33357351-9962328F-B4F8-4BFF-824D-CA31A9CC2689 Q33358921-589B9FDA-77B2-4503-A252-247D0A4CB29C Q33360837-3C70604E-64D9-4453-9509-B33F9F40A801 Q33370887-144991C6-F4DC-40F9-8FD8-B80EEFFD53E5 Q33372127-428F8ED3-2FA9-4FE5-9F9B-6B7B5E39B71C Q33373188-57C42BF6-2ADB-43CF-BD56-D91DD72F0E5E Q33374168-A0B91F42-9FA6-4D85-8AC6-CDB4B0DEB68A Q33374714-E32BF5CC-9D6A-44A7-9272-DEA9AEBF5365 Q33375704-E6B79A52-CAE7-4E7A-85C6-AF846FDAB826 Q33380300-04CE8E93-17B8-4D8A-BD77-2EBA38D2DA5F Q33380427-76B73415-EA06-4CAA-9E49-3C3CF11B4354 Q33382477-34ED79FC-0EA4-4BAA-BECB-9E265A0A4109 Q33383126-BD8500C6-9230-4823-B22B-AD0EA3704FA5 Q33384279-BC42A536-F39A-4124-BDE6-8BFF0C01F2AC Q33387755-77F0E4BE-BFFC-43D1-83EA-3CAB7EA49230 Q33390447-CB16BAF4-0DA9-46A7-8501-60E14503C5C6 Q33391777-D370893E-7DDC-4F10-ABD3-D62C9F195198

P2860

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

http://www.wikidata.org/entity/Q33429552

description

1989 nî lūn-bûn

@nan

1989 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1989 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1989年の論文

@ja

1989年論文

@yue

1989年論文

@zh-hant

1989年論文

@zh-hk

1989年論文

@zh-mo

1989年論文

@zh-tw

1989年论文

@wuu

name

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

@ast

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

@en

type

label

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

@ast

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

@en

prefLabel

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

@ast

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

@en

P1433

Q33429552-82680F84-7A87-4AF4-8246-EAA1B265F05C

P1476

Q33429552-CA31FD38-55E7-41CF-9957-6CEB88E34631

P2093

Q33429552-0D8A6AF5-B20E-4C9C-B519-A087F84EF15D

Q33429552-1F353E0C-374E-45B9-A3FC-B31F925FDF37

Q33429552-1FFDBACD-F3A0-4A04-8600-B5D76807FAAD

Q33429552-2EFC083E-841E-4EF1-9EFB-24BF9D487AF9

Q33429552-2FBFD00B-3839-4B39-B725-1A0F70A2D122

Q33429552-9041FB64-47A2-4CB8-B2BC-C4167A96B9F6

Q33429552-9893B286-7738-4794-A6AE-55A766EA68D4

Q33429552-A7D8CBD1-1F3C-4E47-B836-63794395B7E8

Q33429552-DCB53337-34C4-409A-8FC5-D08F095FDAD0

Q33429552-F0B313C3-81BC-4ACF-B62D-1541F631FF44

P304

Q33429552-4C96D263-667E-43F9-A55E-CFFCA324B761

P31

Q33429552-6A179518-3528-47A6-A623-C3A3274A97D0

P356

Q33429552-ACA65A28-A538-48E1-9ACD-A44CC882D5C3

P407

Q33429552-83815299-1EEE-4917-8597-5262491269D8

P433

Q33429552-D821AA1D-7AEE-4233-94F6-AB74776FDC45

P478

Q33429552-60C9C301-EE81-4B73-A2DE-3286A22B89DE

P577

Q33429552-991F754F-C443-471B-B72D-E377AEAD0EB6

P698

Q33429552-10B48C9A-399B-4C6C-AC7F-7EE9871EEF0A

P356

JCO.1989.7.11.1748

P1433

Journal of Clinical Oncology

P1476

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

@en

P2093

A H Calvert

http://www.w3.org/2001/XMLSchema#string

D R Newell

http://www.w3.org/2001/XMLSchema#string

E Wiltshaw

http://www.w3.org/2001/XMLSchema#string

F E Boxall

http://www.w3.org/2001/XMLSchema#string

I R Judson

http://www.w3.org/2001/XMLSchema#string

L A Gumbrell

http://www.w3.org/2001/XMLSchema#string

M Burnell

http://www.w3.org/2001/XMLSchema#string

M E Gore

http://www.w3.org/2001/XMLSchema#string

S O'Reilly

http://www.w3.org/2001/XMLSchema#string

Z H Siddik

http://www.w3.org/2001/XMLSchema#string

P304

1748-1756

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.1989.7.11.1748

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

1989-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

2681557

http://www.w3.org/2001/XMLSchema#string